Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), said, under the recently announced U.S. strategic partnership agreement, Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira for Quallent Pharmaceuticals with, in alignment with its U.S.

Alvotech（ALVO）和Teva Pharmaceuticals（Teva Pharmaceuticals Industries）的美国附属公司Teva Pharmaceuticals表示，根据最近宣布的美国战略伙伴关系协议，Alvotech将生产高浓度可互换生物仿制药，用于Quallent Pharmaceuticals。

commercialization agreement with Teva. The FDA approved Alvotech's biosimilar on February 24, 2024, as a high-concentration interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn's disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis.In August 2020, Alvotech and Teva entered into a strategic partnership for the exclusive commercialization of five of Alvotech's biosimilar product candidates.

与Teva的商业化协议。2024年2月24日，FDA批准Alvotech的生物仿制药作为Humira的高浓度可互换生物仿制药，用于治疗成人类风湿性关节炎，幼年特发性关节炎，成人银屑病关节炎，成人强直性脊柱炎，克罗恩病，成人溃疡性结肠炎，成人斑块状银屑病，成人化脓性汗腺炎和成人葡萄膜炎。2020年8月，Alvotech和Teva就Alvotech的五种生物仿制药候选产品的独家商业化达成了战略合作伙伴关系。

In August 2023 the companies extended the partnership to include two additional biosimilars and two new presentations of previously partnered products. .

2023年8月，这些公司扩大了合作关系，包括另外两种生物仿制药和两种新的先前合作产品演示。

For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.comBusiness News

有关更多此类健康新闻，请访问rttnews.com。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股